Shanghai Sun-shine Pharmaceutical Technology

Shanghai Sunshine Pharmaceutical Technology is the primary research and development hub for the HEC Group, a prominent Chinese pharmaceutical conglomerate. Established in 2004 and located in Shanghai, the company focuses on the discovery and clinical development of innovative drugs and high-end generics across metabolic diseases, infectious diseases, and oncology. It has successfully developed several key products, including the NS5A inhibitor yimitasvir for Hepatitis C and various insulin analogs such as insulin glargine and insulin aspart. The company operates comprehensive R&D facilities that integrate medicinal chemistry, biologics development, and clinical research to support the global pharmaceutical operations of the HEC Group.